Search results
Added:
2 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open…
View more
Added:
4 months ago
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the…
View more
Added:
4 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy…
View more
Added:
1 year ago
ESC Congress 2024 — The interruption of beta blocker treatment was not non-inferior to a strategy of βB continuation.Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with investigator, Prof Johanne Silvain(Pitié-Salpêtrière University Hospital, Paris, FR) to discuss key results from the AβYSS trial (NCT03498066; Assistance Publique - Hôpitaux de Paris).The ABYSS trial…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac…
View more
Added:
4 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial…
View more
Reverse Remodelling in HFrEF
Added:
1 month ago
Article
GDMT for Heart Failure
Added:
1 year ago
Article
Added:
2 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more